Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMODORE 1: crovalimab versus eculizumab in complement inhibitor-treated PNH
NL-OMON59339Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of crovalimab, eculizumab and ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Roche. Primary endpoints: Incidence and severity of adverse events, Change from baseline in targeted vital signs and 4 more. Started Aug 2021; status: completed.
02
Drugs
crovalimabeculizumabravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON59339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59339.